Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21-99
SponsorNational Cancer Centre, Singapore
About this trial
Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with severe side effects from radiotherapy
Patients with a type of cancer that is associated with sensitivity to radiotherapy
Disqualifiers
Age of patient must be between 21 (inclusive) and 99 (exclusive)
Trial population
Participants will be recruited from patients of the study team when they attend their regular clinic visits or when they are admitted to the hospital. These are patients from NCCS.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
To identify genes or molecular pathways that are associated with radiation sensitivity in blood and tissue samples
Whole exome sequencing, single nucleotide polymorphism (SNP) assays
Time frame
Blood is taken at informed consent; tissue is from archived sample2
Change in immune profile of blood and tissue after radiation
Mass cytometry using CyTOF technology will be used to detect the immune cell population
Time frame
Blood is taken at informed consent; tissue is from archived sample3
To identify proteins that are associated with radiation sensitivity in tissue samples
Immunohistochemistry will be used to detect protein expression
Time frame
Tissue is from archived sample4
To identify RNA expression pathways that are associated with radiation sensitivity in blood and tissue samples
RNA sequencing
Time frame
Blood is taken at informed consent; tissue is from archived sampleSponsors and contacts
Click on the lead sponsor to view all of their trials.
National Cancer Centre, Singapore
Lead sponsor
National Medical Research Council (NMRC), Singapore
Collaborator
Duke-NUS Graduate Medical School
Collaborator
Ferring Pharmaceuticals
Collaborator
ImmunoSCAPE
Collaborator
Decipher Biosciences
Collaborator
Source ClinicalTrials.gov